- Home
- CELU vs JSPR Comparison
CELU vs JSPR Comparison
Compare CELU & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | JSPR |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | United States | United States |
| Employees | 115 | 22 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 14.9M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CELU | JSPR |
|---|---|---|
| Price | $0.73 | $0.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $6.00 | ★ $15.50 |
| AVG Volume (30 Days) | 168.4K | ★ 470.8K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $76.00 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.56 | $0.32 |
| 52 Week High | $4.35 | $4.00 |
Technical Indicators
Market Signals| Indicator | CELU | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 47.55 | 43.85 |
| Support Level | $0.69 | $0.42 |
| Resistance Level | $0.96 | $0.60 |
| Average True Range (ATR) | 0.08 | 0.07 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 53.22 | 55.53 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About JSPR Jasper Therapeutics Inc.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.